Incannex Healthcare (IXHL) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NanoViricides (NNVC) has outperformed Incannex Healthcare (IXHL) over the past year, losing 8.4% versus a loss of 75.3%. Incannex Healthcare is the larger company by market cap ($40.1 million vs $33.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | NNVC |
|---|---|---|
| Share price | $3.20 | $1.31 |
| Market cap | $40.14M | $33.44M |
| 1-day change | +0.63% | -9.03% |
| YTD return | -70.20% | +15.93% |
| 1-year return | -75.31% | -8.39% |
| 5-year return | — | -73.16% |
| EPS (TTM) | $-1.66 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $2.23 |
| 52-week low | $2.49 | $0.85 |
| Distance from 52-week high | -78.54% | -41.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +483.75% | +358.02% |
| Average volume | 94.75K | 445.00K |
| Shares outstanding | 12.54M | 25.52M |
| Employees | 12 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed IXHL by 66.9 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Healthcare · Biotechnology · 7 employees
IXHL vs NNVC FAQ
Which is bigger, Incannex Healthcare or NanoViricides?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $40.14M compared with $33.44M for NanoViricides (NNVC).
Which stock has performed better over the past year, IXHL or NNVC?
NNVC returned -8.39% over the past 12 months, compared with -75.31% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and NanoViricides in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Incannex Healthcare and Biotechnology for NanoViricides.